Moderna Inc. shares surged 6.68% as the stock reached a 20-day high, reflecting strong investor sentiment.
The company announced an upgraded revenue forecast of $1.9 billion for 2025, which is $100 million above previous estimates, enhancing investor confidence. Additionally, Moderna has improved its GAAP operating expense forecast by $200 million, expecting a year-end cash balance of $8.1 billion, which further solidifies its financial position. This positive outlook has driven the stock price up significantly, showcasing a robust recovery in market sentiment.
The implications of this revenue upgrade are substantial, as it not only reflects the company's strong market position but also indicates a positive trajectory for future growth. Investors are likely to remain optimistic as Moderna continues to innovate and expand its product offerings.
Wall Street analysts forecast MRNA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRNA is 29.36 USD with a low forecast of 17.00 USD and a high forecast of 63.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
Wall Street analysts forecast MRNA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRNA is 29.36 USD with a low forecast of 17.00 USD and a high forecast of 63.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
14 Hold
4 Sell
Hold
Current: 39.360
Low
17.00
Averages
29.36
High
63.00
Current: 39.360
Low
17.00
Averages
29.36
High
63.00
Wedbush
Outperform
maintain
$26 -> $37
Al Analysis
2026-01-07
Reason
Wedbush
Price Target
$26 -> $37
Al Analysis
2026-01-07
maintain
Outperform
Reason
Wedbush raised the firm's price target on Monte Rosa Therapeutics to $37 from $26 and keeps an Outperform rating on the shares after the company announced positive interim data from an ongoing Phase 1 clinical study evaluating MRT-8102 for the treatment of inflammatory conditions. Monte Rosa also expects to initiate a Phase 2 study in atherosclerotic cardiovascular disease patients in 2026, and is currently evaluating additional potential indications including metabolic dysfunction-associated steatohepatitis, gout, and recurrent pericarditis, notes the analyst, who is updating the firm's model to include credit for ASCVD for MRT-8102.
LifeSci Capital
analyst
Outperform
maintain
2026-01-07
Reason
LifeSci Capital
analyst
Price Target
2026-01-07
maintain
Outperform
Reason
After Monte Rosa announced an update with data from the placebo-controlled Phase 1 trial testing their NEK7-targeted molecular glue degrader, called MRT-8102, LifeSci Capital says that today's initial data will continue to "strongly support investor interest" in the NEK7 MGD program. Given the importance of hsCRP reductions across a range of cardiovascular diseases, it's "not a tremendous surprise to us that the stock is up pre-market," adds the analyst, who has an Outperform rating and a "favorable view on today's dataset."
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MRNA
Unlock Now
Jefferies
Buy
maintain
$22 -> $31
2026-01-07
Reason
Jefferies
Price Target
$22 -> $31
2026-01-07
maintain
Buy
Reason
Jefferies raised the firm's price target on Monte Rosa Therapeutics to $31 from $22 and keeps a Buy rating on the shares after MRT-8102 showed deep reduction of inflammatory biomarker hsCRP in healthy volunteers and subjects with elevated cardiovascular risk in a Phase 1 study. The firm sees the data providing "strong" early proof of concept with broad potential across cardiometabolic diseases, the analyst tells investors.
BofA
Tim Anderson
Underperform
maintain
$21 -> $24
2026-01-06
Reason
BofA
Tim Anderson
Price Target
$21 -> $24
2026-01-06
maintain
Underperform
Reason
BofA analyst Tim Anderson raised the firm's price target on Moderna to $24 from $21 and keeps an Underperform rating on the shares. Moderna has done "a solid job" of cost cutting from COVID highs, though the firm expects shares will continue to trade around COVID uptake and sentiment in the near-term, with headwinds unlikely to meaningfully abate into the 2026/2027 season, the analyst tells investors.
About MRNA
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
